Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SNGX with free AI briefings, catalyst countdowns, and dilution alerts.

SNGX · SOLIGENIX, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$9M Cash on Hand
17.3mo Cash Runway
Follow SNGX by email Get an email when SNGX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SNGX, unsubscribe in one click. Privacy

📣 What SNGX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Hypericin CTCL/ Mycosis Fungoides Phase 3 · NCT06470451 Terminated
Protein Phosphatase Mn(2+)-Dependent 1K Acute Gastrointestinal Graft vs Host Disease Phase 3 · NCT00926575 Terminated
Dusquetide (SGX942) Squamous Cell Carcinoma of the Oral Cavity and Oropharynx Phase 3 · NCT03237325 Completed
SGX201 (delayed release beclomethasone… Enteritis Phase 1/2 · NCT01073384 Completed

Also used in these trials (approved or third-party drugs, not SNGX's own candidates): Mechlorethamine Hydrochloride.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SNGX holds $9M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.6M/quarter from operations, an estimated runway of 17.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 68 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SNGX files for a raise →

👥 Who Owns SNGX

Insiders 0.1% Other 5%+ holders 4.2% Institutions 8.8% Public and other holders 86.9%
HolderTypeShares% of sharesAs of
MJL Manager LLC Institution (13G, 5%+) 2,053,706 8.79% 2026-09-30
Michael Liu 5%+ holder (13G) 983,588 4.21% 2026-06-22
Christopher J Schaber
CHAIRMAN, CEO AND PRESIDENT, Director · +395,000 options
Insider 15,511 0.07% 2025-10-02

Share count 23,368,754 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SNGX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SNGX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.